These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Germline and Somatic You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z Front Oncol; 2020; 10():295. PubMed ID: 32211327 [No Abstract] [Full Text] [Related]
23. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues. Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553 [TBL] [Abstract][Full Text] [Related]
24. The Features of Luo Y; Wu H; Huang Q; Rao H; Yu Z; Zhong Z Int J Gen Med; 2022; 15():2773-2786. PubMed ID: 35300142 [TBL] [Abstract][Full Text] [Related]
25. Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Ashour M; Ezzat Shafik H Cancer Manag Res; 2019; 11():6275-6284. PubMed ID: 31372034 [TBL] [Abstract][Full Text] [Related]
26. BRCA1 germline mutations may be associated with reduced ovarian reserve. Wang ET; Pisarska MD; Bresee C; Chen YD; Lester J; Afshar Y; Alexander C; Karlan BY Fertil Steril; 2014 Dec; 102(6):1723-8. PubMed ID: 25256924 [TBL] [Abstract][Full Text] [Related]
27. Germline Mehta A; Vasudevan S; Sharma SK; Kumar D; Panigrahi M; Suryavanshi M; Gupta G Cancer Manag Res; 2018; 10():6505-6516. PubMed ID: 30555256 [TBL] [Abstract][Full Text] [Related]
28. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome. Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S; Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635 [TBL] [Abstract][Full Text] [Related]
29. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines. So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392 [TBL] [Abstract][Full Text] [Related]
30. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854 [TBL] [Abstract][Full Text] [Related]
31. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428 [TBL] [Abstract][Full Text] [Related]
32. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer. Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and BRCA1/BRCA2 pathogenic variants of patients with breast cancer. Eras N; Tuncel F; Altıntas Z; Erden S Pol J Pathol; 2024; 75(1):1-7. PubMed ID: 38741424 [TBL] [Abstract][Full Text] [Related]
35. Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging. Saida T; Shikama A; Mori K; Ishiguro T; Minaguchi T; Satoh T; Nakajima T Magn Reson Med Sci; 2024 Jan; 23(1):18-26. PubMed ID: 36372398 [TBL] [Abstract][Full Text] [Related]